Cargando…
Long-Term Follow-Up of a Severe Eosinophilic Asthmatic Patient With Comorbid Nasal Polyposis Hospitalized for SARS-CoV-2 Infection While Receiving Benralizumab: A Case Report
We report a case of a patient affected by severe eosinophilic asthma with nasal polyps (SEA+NP) who developed coronavirus disease 2019 (COVID-19) six months after starting benralizumab as add-on therapy. Both SEA and NP were under control with no exacerbations at the time of severe acute respiratory...
Autor principal: | Ambrosino, Annamaria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752115/ https://www.ncbi.nlm.nih.gov/pubmed/35036198 http://dx.doi.org/10.7759/cureus.20364 |
Ejemplares similares
-
Exacerbation of Eosinophilic Granulomatosis With Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis With Nasal Polyposis
por: Tanaka, Shunya, et al.
Publicado: (2022) -
COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth
por: Renner, Andreas, et al.
Publicado: (2020) -
Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma
por: Lombardo, Nicola, et al.
Publicado: (2020) -
Effectiveness of Benralizumab in Improving the Quality of Life of Severe Eosinophilic Asthmatic Patients: Our Real-Life Experience
por: Scioscia, Giulia, et al.
Publicado: (2021) -
Effect of benralizumab in a patient with uncontrolled severe eosinophilic asthma and comorbid chronic rhinosinusitis with nasal polyps refractory to mepolizumab treatment
por: Mansur, Adel H.
Publicado: (2021)